Science

Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study

Herbert Loong/immunooncologyindia.com

Apr 7, 2025, 11:42

Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study

Herbert Loong, Chair-Elect of the International Affairs Committee at American Society of Clinical Oncology (ASCO), shared an article by A.C. Chiang, et al. on LinkedIn:

“Happy to share our recent ESMO Open paper on the safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy.

Luis Paz-Ares, Noemi Reguart, Shirish Gadgeel and others.”

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.

Authors: A.C. Chiang, et al.

Herbert Loong: The safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study

American Society of Clinical Oncology ASCO cancer DeLLphi300 ESMO Open fight against cancer Global fight against cancer Herbert Loong Luis Paz-Ares Noemi Reguart OncoDaily Oncology Shirish Gadgeel Tarlatamab

Oliver Bogler Announced the Launch of the NanCI AI Webapp for Scientific Literature and Networking

Joe Biden Diagnosed with Aggressive Metastatic Prostate Cancer at Age 82

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial

New World Cancer Declaration 2025–2035 by UICC